We are live on
!
Find out more
Mitsubishi UFJ Asset Management Portfolio holdings
AUM
$180B
1-Year Est. Return
37.51%
This Fund
S&P 500
This Quarter
Est. Return
+8.91%
1 Year Est. Return
+37.51%
3 Year Est. Return
+115.4%
5 Year Est. Return
+142.39%
10 Year Est. Return
+552.78%
AUM
$47.9B
AUM Growth
+$5.83B
(+14%)
Cap. Flow
+$2.54B
Cap. Flow
% of AUM
5.29%
Top 10 Holdings %
Top 10 Hldgs %
27.7%
Holding
1,160
New
43
Increased
790
Reduced
196
Closed
50
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Arthur J. Gallagher & Co
AJG
|
+$236M |
| 2 |
Apple
AAPL
|
+$145M |
| 3 |
Accenture
ACN
|
+$128M |
| 4 |
IQVIA
IQV
|
+$97.2M |
| 5 |
Thermo Fisher Scientific
TMO
|
+$85.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Medtronic
MDT
|
+$238M |
| 2 |
Baxter International
BAX
|
+$147M |
| 3 |
Adobe
ADBE
|
+$80.4M |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$68.9M |
| 5 |
Microsoft
MSFT
|
+$55M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 29.48% |
| 2 | Healthcare | 16.05% |
| 3 | Financials | 13.32% |
| 4 | Consumer Discretionary | 8.73% |
| 5 | Industrials | 7.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
RNAM
1001
DELISTED
Avidity Biosciences
RNAM
| $267K | ﹤0.01% |
24,109
+1,108
| +5% | +$13.9K |
|
1002
Vir Biotechnology
VIR
$1.5B
| $265K | ﹤0.01% |
10,807
+857
| +9% | +$21.5K |
|
1003
BioNTech
BNTX
$23.3B
| $264K | ﹤0.01% |
2,446
+821
| +51% | +$92.3K |
|
1004
4D Molecular Therapeutics
FDMT
$582M
| $261K | ﹤0.01% |
14,458
+2,422
| +20% | +$44.6K |
|
1005
GDS Holdings
GDS
$6.29B
| $254K | ﹤0.01% |
23,100
-30,300
| -57% | -$403K |
|
1006
Beam Therapeutics
BEAM
$2.82B
| $253K | ﹤0.01% |
+7,931
| New | +$257K |
|
1007
Ultragenyx Pharmaceutical
RARE
$2.64B
| $253K | ﹤0.01% |
5,489
-2,328
| -30% | -$108K |
|
1008
Intellia Therapeutics
NTLA
$1.68B
| $253K | ﹤0.01% |
6,200
+647
| +12% | +$26.2K |
|
1009
BridgeBio Pharma
BBIO
$16.6B
| $251K | ﹤0.01% |
14,569
-6,474
| -31% | -$97.4K |
|
|
ONL
1010
Orion Office REIT
ONL
$157M
| $250K | ﹤0.01% |
37,889
+11,070
| +41% | +$69K |
|
1011
Iovance Biotherapeutics
IOVA
$2.9B
| $249K | ﹤0.01% |
35,428
-7,161
| -17% | -$51.3K |
|
1012
Fate Therapeutics
FATE
$322M
| $249K | ﹤0.01% |
52,383
+39,734
| +314% | +$219K |
|
1013
Xencor
XNCR
$1.6B
| $249K | ﹤0.01% |
9,978
+296
| +3% | +$8.05K |
|
1014
Forum Energy Technologies
FET
$882M
| $248K | ﹤0.01% |
+9,704
| New | +$230K |
|
1015
Rocket Pharmaceuticals
RCKT
$397M
| $248K | ﹤0.01% |
12,496
-3,896
| -24% | -$78.7K |
|
1016
CRISPR Therapeutics
CRSP
$5.17B
| $247K | ﹤0.01% |
4,408
-272
| -6% | -$15.4K |
|
1017
Upstart Holdings
UPST
$2.94B
| $244K | ﹤0.01% |
6,822
-2,887
| -30% | -$66.4K |
|
|
TSVT
1018
DELISTED
2seventy bio
TSVT
| $243K | ﹤0.01% |
23,981
+6,722
| +39% | +$71.2K |
|
1019
Editas Medicine
EDIT
$432M
| $242K | ﹤0.01% |
29,387
+4,678
| +19% | +$40.8K |
|
1020
Maravai LifeSciences
MRVI
$904M
| $242K | ﹤0.01% |
19,449
+815
| +4% | +$11K |
|
|
BLUE
1021
DELISTED
bluebird bio
BLUE
| $241K | ﹤0.01% |
3,662
+1,766
| +93% | +$129K |
|
1022
Recursion Pharmaceuticals
RXRX
$1.76B
| $232K | ﹤0.01% |
31,064
+10,285
| +49% | +$72K |
|
1023
dLocal
DLO
$4.23B
| $226K | ﹤0.01% |
18,542
+3,832
| +26% | +$50.6K |
|
1024
AbCellera Biologics
ABCL
$2.85B
| $221K | ﹤0.01% |
34,214
+19,083
| +126% | +$130K |
|
1025
Riot Platforms
RIOT
$7.34B
| $221K | ﹤0.01% |
18,666
-22,593
| -55% | -$253K |
|
Similar funds
VGA
Mitsubishi UFJ Asset Management's Q2 2023 Portfolio in Review
As of Q2 2023, Mitsubishi UFJ Asset Management held 1,160 positions worth $47.9B, up 14% from $42.1B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Mitsubishi UFJ Asset Management deployed $2.54B of net new capital in Q2 2023, opening 43 new positions and adding to 790 existing holdings. Its largest new stake was Builders FirstSource: 52,050 shares worth $7.08M.
By sector, the portfolio is most concentrated in Technology at 29% of assets, up from 28% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Medtronic, an estimated $238M trimmed.
- Mitsubishi UFJ Asset Management's largest Q2 2023 buy was Builders FirstSource: 52,050 shares worth $7.08M.
- Mitsubishi UFJ Asset Management added most to Arthur J. Gallagher & Co in Q2 2023, an estimated $236M increase.
- Mitsubishi UFJ Asset Management's biggest Q2 2023 reduction was Medtronic, cutting an estimated $238M.
- Mitsubishi UFJ Asset Management fully exited Trip.com Group in Q2 2023, selling an estimated $9.25M.
- Mitsubishi UFJ Asset Management's ten largest holdings make up 28% of its $47.9B portfolio in Q2 2023.
- Mitsubishi UFJ Asset Management opened 43 new positions and closed 50 in Q2 2023.
- Mitsubishi UFJ Asset Management's portfolio value rose 14% quarter-over-quarter to $47.9B.
Based on Mitsubishi UFJ Asset Management's 13F filing for Q2 2023, filed 9 Aug 2023.